NASDAQ:STOK - Stoke Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $60.14
  • Forecasted Upside: 96.16 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.47 (-1.51%)

This chart shows the closing price for STOK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Stoke Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STOK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STOK

Analyst Price Target is $60.14
▲ +96.16% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Stoke Therapeutics in the last 3 months. The average price target is $60.14, with a high forecast of $76.00 and a low forecast of $35.00. The average price target represents a 96.16% upside from the last price of $30.66.

This chart shows the closing price for STOK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in Stoke Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2021UBS GroupInitiated CoverageNeutral$35.00Low
5/10/2021WedbushUpgradeNeutral ➝ OutperformLow
3/11/2021Canaccord GenuityBoost Price TargetBuy$72.00 ➝ $76.00Medium
3/10/2021Credit Suisse GroupBoost Price TargetOutperform$49.00 ➝ $58.00Medium
2/10/2021WedbushDowngradeOutperform ➝ NeutralLow
1/14/2021Needham & Company LLCBoost Price TargetPositive ➝ Buy$56.00 ➝ $65.00High
12/28/2020Canaccord GenuityBoost Price TargetBuy$53.00 ➝ $72.00N/A
12/15/2020HC WainwrightReiterated RatingBuy$70.00Low
12/11/2020Needham & Company LLCBoost Price TargetBuy$48.00 ➝ $56.00Low
11/13/2020Canaccord GenuityBoost Price TargetBuy$49.00 ➝ $53.00High
11/13/2020BTIG ResearchBoost Price TargetBuy$46.00 ➝ $68.00High
11/13/2020Credit Suisse GroupBoost Price TargetOutperform$42.00 ➝ $49.00Medium
10/23/2020Cantor FitzgeraldInitiated CoverageOverweight$49.00High
9/29/2020Needham & Company LLCInitiated CoverageBuy$42.00Low
9/29/2020JPMorgan Chase & Co.Initiated CoverageNeutralLow
8/11/2020HC WainwrightReiterated RatingBuy$30.00Medium
7/9/2020Canaccord GenuityReiterated RatingBuy$44.00High
6/26/2020Canaccord GenuityReiterated RatingBuy$44.00High
5/18/2020HC WainwrightReiterated RatingBuy$30.00High
3/23/2020CowenReiterated RatingBuyLow
12/17/2019WedbushInitiated CoverageOutperform$31.00Medium
12/9/2019HC WainwrightReiterated RatingBuy$30.00High
12/3/2019JPMorgan Chase & Co.Lower Price TargetOverweight$34.00 ➝ $33.00High
11/12/2019BTIG ResearchInitiated CoverageBuy$46.00High
10/25/2019HC WainwrightInitiated CoverageBuy$30.00High
8/15/2019CowenReiterated RatingBuyLow
7/15/2019Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$35.00Medium
7/15/2019Canaccord GenuityInitiated CoverageBuy ➝ Buy$44.00Medium
7/15/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$34.00Medium
7/15/2019CowenInitiated CoverageOutperform ➝ OutperformMedium
(Data available from 7/23/2016 forward)
Stoke Therapeutics logo
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: $30.66
Low: $30.15
High: $31.83

50 Day Range

MA: $35.86
Low: $30.66
High: $41.09

52 Week Range

Now: $30.66
Low: $24.18
High: $71.58


52,609 shs

Average Volume

171,587 shs

Market Capitalization

$1.13 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Stoke Therapeutics?

The following Wall Street research analysts have issued research reports on Stoke Therapeutics in the last twelve months: BTIG Research, Canaccord Genuity, Cantor Fitzgerald, Credit Suisse Group AG, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, UBS Group AG, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for STOK.

What is the current price target for Stoke Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Stoke Therapeutics in the last year. Their average twelve-month price target is $60.14, suggesting a possible upside of 96.2%. Canaccord Genuity has the highest price target set, predicting STOK will reach $76.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $35.00 for Stoke Therapeutics in the next year.
View the latest price targets for STOK.

What is the current consensus analyst rating for Stoke Therapeutics?

Stoke Therapeutics currently has 2 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STOK will outperform the market and that investors should add to their positions of Stoke Therapeutics.
View the latest ratings for STOK.

What other companies compete with Stoke Therapeutics?

How do I contact Stoke Therapeutics' investor relations team?

Stoke Therapeutics' physical mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company's listed phone number is 781-430-8200 and its investor relations email address is [email protected] The official website for Stoke Therapeutics is